Christopher Richard Anzalone Arrowhead Pharmaceuticals, Inc. (ARWR) insider trading activity

Christopher Richard Anzalone is Chief Executive Officer of ARROWHEAD PHARMACEUTICALS, INC.. Currently has a direct ownership of 4.06 Million shares of ARWR, which is worth approximately $56.1 Million. The most recent transaction as insider was on Jul 08, 2022, when has been sold 551,197 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.06M

7.59% 3M change

9.35% 12M change

Total Value Held $56.1 Million

Christopher Richard Anzalone Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 08 2022	SELL Sale (or disposition) back to the issuer	-	551,197 Reduced 13.58%	3,508,938 Common Stock
Jul 07 2022	BUY Exercise of conversion of derivative security	$36,365 $14.54 p/Share	2,501 Added 0.06%	4,060,135 Common Stock
Feb 11 2022	SELL Open market or private sale	$7,568,260 $51.7 p/Share	146,388 Reduced 3.48%	4,057,634 Common Stock
Feb 11 2022	BUY Exercise of conversion of derivative security	$759,754 $5.19 p/Share	146,388 Added 3.36%	4,204,022 Common Stock
Jan 07 2022	BUY Exercise of conversion of derivative security	$61,273 $5.19 p/Share	11,806 Added 0.29%	4,057,634 Common Stock
Jan 01 2022	BUY Grant, award, or other acquisition	-	800,000 Added 16.51%	4,045,828 Common Stock
Dec 23 2021	BUY Exercise of conversion of derivative security	$61,273 $5.19 p/Share	11,806 Added 0.36%	3,245,828 Common Stock
Dec 15 2021	SELL Open market or private sale	$4,096,800 $68.28 p/Share	60,000 Reduced 1.83%	3,219,022 Common Stock
Oct 22 2021	SELL Open market or private sale	$3,291,500 $65.83 p/Share	50,000 Reduced 1.5%	3,279,022 Common Stock
Oct 20 2021	SELL Open market or private sale	$993,450 $66.23 p/Share	15,000 Reduced 0.45%	3,329,022 Common Stock
Jan 01 2021	BUY Grant, award, or other acquisition	-	800,000 Added 19.3%	3,344,022 Common Stock
Dec 30 2020	SELL Bona fide gift	-	599 Reduced 0.02%	2,544,022 Common Stock
Dec 28 2020	SELL Bona fide gift	-	1,126 Reduced 0.04%	2,544,621 Common Stock
Dec 18 2020	BUY Exercise of conversion of derivative security	$220,779 $5.45 p/Share	40,510 Added 1.57%	2,545,747 Common Stock
Dec 09 2020	SELL Open market or private sale	$2,703,066 $69.89 p/Share	38,676 Reduced 1.52%	2,505,237 Common Stock
Dec 09 2020	BUY Exercise of conversion of derivative security	$77,739 $2.01 p/Share	38,676 Added 1.5%	2,543,913 Common Stock
Dec 08 2020	SELL Open market or private sale	$1,109,542 $67.97 p/Share	16,324 Reduced 0.65%	2,505,237 Common Stock
Dec 08 2020	BUY Exercise of conversion of derivative security	$32,811 $2.01 p/Share	16,324 Added 0.64%	2,521,561 Common Stock
Oct 23 2020	SELL Open market or private sale	$5,837,000 $58.37 p/Share	100,000 Reduced 3.84%	2,505,237 Common Stock

CRA

Christopher Richard Anzalone

Chief Executive Officer

Pasadena, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARWR shares.

Notify only if

Value

Insider Trading

Get notified when an Arrowhead Pharmaceuticals, Inc. insider buys or sells ARWR shares.

Notify only if

Operation

Value

Type

News

Receive news related to ARROWHEAD PHARMACEUTICALS, INC.

Track Activities on ARWR

Account